<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Bone marrow transplantation has become the treatment of choice for patients with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> who are fortunate enough to have allogeneic sibling donors </plain></SENT>
<SENT sid="1" pm="."><plain>As patients have been transplanted earlier in the course of their disease, significant improvements have been obtained in long-term survival </plain></SENT>
<SENT sid="2" pm="."><plain>However, in patients who have been sensitized by previous blood product transfusions, graft rejection continues to be a significant problem and second transplants when performed are frequently unsuccessful </plain></SENT>
<SENT sid="3" pm="."><plain>This case report deals with a patient with <z:hpo ids='HP_0100614'>myositis</z:hpo> ossificans progressiva (MOP) who developed severe idiopathic <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>He rejected his first graft after 160 days </plain></SENT>
<SENT sid="5" pm="."><plain>However, he was successfully reingrafted with marrow from the same donor using a different conditioning regimen </plain></SENT>
</text></document>